Hepatitis B virus core‐related antigen levels predict progression to liver cirrhosis in hepatitis B carriers

Hepatitis B virus core‐related antigen levels predict progression to liver cirrhosis in... IntroductionChronic hepatitis B (CHB) affects over 350 million people worldwide. Long‐term complications of infection include liver cirrhosis and hepatocellular carcinoma (HCC), which together cause over 500 000 deaths annually. Hepatitis B surface antigen (HBsAg)‐positive patients have a 70‐fold increased risk of developing HCC than their HBsAg‐negative counterparts. Hepatitis B virus (HBV) infection is endemic in South‐East Asia, China, Taiwan, Korea, and sub‐Saharan Africa, where up to 85–95% of patients with HCC are HBsAg positive. The risk of progression to cirrhosis and HCC is variable and depends on the host's immune response. The 5‐year cumulative incidence of cirrhosis ranges from 8% to 20% in untreated CHB patients. Among those with cirrhosis, the 5‐year cumulative risk of hepatic decompensation is 20%. The annual risk of HCC in patients with cirrhosis has been reported to be 2–5%.Previous studies have shown that serum levels of HBV DNA and HBsAg are associated with disease progression in patients with CHB. In particular, patients with serum HBV DNA levels ≥ 3.3 log IU/mL (2000 IU/mL) at baseline have an increased likelihood of developing hepatitis B e antigen (HBeAg)‐negative hepatitis, cirrhosis, and HCC during long‐term follow‐up. Apart from these viral parameters, HBV core‐related antigen (HBcrAg), a new biomarker of HBV infection, is http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Gastroenterology and Hepatology Wiley

Hepatitis B virus core‐related antigen levels predict progression to liver cirrhosis in hepatitis B carriers

Loading next page...
 
/lp/wiley/hepatitis-b-virus-core-related-antigen-levels-predict-progression-to-agI0RLHeaH
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
© 2018 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd
ISSN
0815-9319
eISSN
1440-1746
D.O.I.
10.1111/jgh.13989
Publisher site
See Article on Publisher Site

Abstract

IntroductionChronic hepatitis B (CHB) affects over 350 million people worldwide. Long‐term complications of infection include liver cirrhosis and hepatocellular carcinoma (HCC), which together cause over 500 000 deaths annually. Hepatitis B surface antigen (HBsAg)‐positive patients have a 70‐fold increased risk of developing HCC than their HBsAg‐negative counterparts. Hepatitis B virus (HBV) infection is endemic in South‐East Asia, China, Taiwan, Korea, and sub‐Saharan Africa, where up to 85–95% of patients with HCC are HBsAg positive. The risk of progression to cirrhosis and HCC is variable and depends on the host's immune response. The 5‐year cumulative incidence of cirrhosis ranges from 8% to 20% in untreated CHB patients. Among those with cirrhosis, the 5‐year cumulative risk of hepatic decompensation is 20%. The annual risk of HCC in patients with cirrhosis has been reported to be 2–5%.Previous studies have shown that serum levels of HBV DNA and HBsAg are associated with disease progression in patients with CHB. In particular, patients with serum HBV DNA levels ≥ 3.3 log IU/mL (2000 IU/mL) at baseline have an increased likelihood of developing hepatitis B e antigen (HBeAg)‐negative hepatitis, cirrhosis, and HCC during long‐term follow‐up. Apart from these viral parameters, HBV core‐related antigen (HBcrAg), a new biomarker of HBV infection, is

Journal

Journal of Gastroenterology and HepatologyWiley

Published: Jan 1, 2018

Keywords: ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off